Video

Karen Ignagni Calls for Greater Transparency in Pharmaceutical Pricing

No entity in healthcare should have a blank check, but that's the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America's Health Insurance Plans.

No entity in healthcare should have a blank check, but that’s the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America’s Health Insurance Plans.

Her association has been trying to create a dialogue with pharmaceutical companies to find a way for greater transparency in pricing.

“We want to create sustainable innovation,” she said. “There’s no question. Every American wants that. But at the same time we’re not going to be able to create sustainable innovation unless we have such sustainable pricing.”

Related Videos
Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital
Io Hui, PhD, researcher at The University of Edinburgh
Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel
Adam Colborn, JD, of AMCP
Corey McEwen, PharmD, MS
Daniel Howell, MBBS
Jonathan Kurman, MD
Tetyana Kendzerska, MD
Krunal Patel, MD
Scott Manaker,MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo